Hope At ASH For Failed Pfizer Leukemia Drug Mylotarg
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer is talking about “a path forward” for Mylotarg, the leukemia therapy it pulled off the U.S. market in 2010 for lack of both efficacy and safety, after independent French researchers tried it successfully in a different population using a different regimen from the failed confirmatory trial that sunk the antibody-drug conjugate.
You may also be interested in...
Although Pfizer's voluntary withdrawal of its acute myeloid leukemia therapy Mylotarg is the first complete withdrawal of an accelerated approval NDA, but as in other cases where the confirmatory trial fails to substantiate the initial signs of efficacy that supported the accelerated approval, FDA is not completely closing the door on access to the drug
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.